
Mona A Karlsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3655728/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Survival in Women Diagnosed With Breast Cancer During Pregnancy. Clinical Breast Cancer, 2022, 22, e517-e525.	2.4	5
2	Cancer in pregnancy and the risk of adverse pregnancy and neonatal outcomes: A nationwide cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1492-1502.	2.3	11
3	Long-Term Morbidity and Mortality in Children After In Utero Exposure to Maternal Cancer. Journal of Clinical Oncology, 2022, 40, 3975-3984.	1.6	2
4	MicroRNA characteristics in epithelial ovarian cancer. PLoS ONE, 2021, 16, e0252401.	2.5	4
5	Association of Chemotherapy Timing in Pregnancy With Congenital Malformation. JAMA Network Open, 2021, 4, e2113180.	5.9	27
6	Cancer in pregnancy increases the risk of venous thromboembolism: a nationwide cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 1151-1159.	2.3	11
7	Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. Anticancer Research, 2019, 39, 2475-2482.	1.1	9
8	Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4. International Journal of Gynecological Cancer, 2019, 29, 1304-1310.	2.5	1
9	Survival of selected patients with ovarian cancer treated with fertility-sparing surgery. Reproductive BioMedicine Online, 2018, 37, 71-76.	2.4	10
10	Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer. PLoS ONE, 2018, 13, e0207319.	2.5	35
11	Appreciable uncertainty regarding benefits and risks in the treatment of bacterial vaginosis to prevent preterm birth. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 251-252.	2.8	4
12	Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. PLoS ONE, 2017, 12, e0174300.	2.5	11
13	Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery – a clinical recommendation. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 850-860.	2.8	57
14	HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer. Apmis, 2016, 124, 1038-1045.	2.0	10
15	Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). Gynecologic Oncology, 2016, 142, 50-53.	1.4	33
16	A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC–IV ovarian cancer—a part of the Danish prospective pelvic mass study. Tumor Biology, 2016, 37, 12619-12626.	1.8	19
17	High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infectious Agents and Cancer, 2016, 11, 39.	2.6	20
18	Primary hyperaldosteronism diagnosed with adrenal vein sampling. Characteristics and follow-up after adrenalectomy in a Danish study. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 45-50.	1.2	8

Mona A Karlsen

#	Article	IF	CITATIONS
19	The prognostic value of dividing epithelial ovarian cancer into type I and type II tumors based on pathologic characteristics. Gynecologic Oncology, 2015, 136, 205-211.	1.4	30
20	Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities — A systematic review. Gynecologic Oncology, 2015, 136, 571-581.	1.4	27
21	A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer — An international multicenter study in women with an ovarian mass. Gynecologic Oncology, 2015, 138, 640-646.	1.4	78
22	HE4 Tissue Expression and Serum HE4 Levels in Healthy Individuals and Patients with Benign or Malignant Tumors: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2285-2295.	2.5	65
23	Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 477-484.	1.2	10
24	Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 2012, 127, 379-383.	1.4	187